A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Clinical trial NCT04049825 · COMPLETED

Trial details

NCT number: NCT04049825
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Start date: 2019-11-22
Primary completion: 2025-03-25
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.